Prazosin

alpha-Adrenergic Blocker — CARDIOVASCULAR SYSTEM

Key facts

Prazosin is an ofp drug in the alpha-Adrenergic Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1976. Its mechanism of action is classified as Adrenergic alpha-Antagonists. DrugCentral lists 40 molecular targets, including Adra1b|Adra1d|Adra1a, ADRA1A and Adra1a. Recorded indications include Hypertensive disorder.

• Approval status: ofp (first approved 1976 by the FDA).
• Drug class: alpha-Adrenergic Blocker.
• Mechanism of action: Adrenergic alpha-Antagonists.
• Molecular targets: Adra1b|Adra1d|Adra1a, ADRA1A, Adra1a and Adra1b (40 listed in DrugCentral).
• Indications: Hypertensive disorder.
• ATC code: C02CA01 (Alpha-adrenoreceptor antagonists).
• Molecular formula: C19H21N5O4; molecular weight 383.41 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Hypertensive disorder

Off-label uses (3)

• Benign prostatic hyperplasia
• Chronic Post Traumatic Stress Disorder with Trauma-related Nightmares
• PTSD related nightmares

Contraindications (6)

• Cataract surgery
• End stage renal disease
• Intraoperative floppy iris syndrome
• Micturition syncope
• Narcolepsy
• Syncope

Mechanism & targets

• Mechanism of action (MoA): Adrenergic alpha-Antagonists
• Established pharmacologic class: alpha-Adrenergic Blocker

Molecular targets (40)

Target	Gene	Action	Activity
Adrenergic receptor alpha-1	Adra1b|Adra1d|Adra1a	unknown	Kd 10.99
Alpha-1A adrenergic receptor	ADRA1A	inverse agonist	Ki 10.40
Alpha-1A adrenergic receptor	Adra1a	unknown	Ki 10.15
Alpha-1B adrenergic receptor	Adra1b	unknown	Ki 10.00
Alpha-1A adrenergic receptor	ADRA1A	unknown	Ki 9.77
Alpha-1D adrenergic receptor	Adra1d	unknown	Ki 9.70
Alpha-1D adrenergic receptor	ADRA1D	inverse agonist	Ki 9.70
Mu-type opioid receptor	Oprm1	unknown	Ki 9.70
Alpha-1B adrenergic receptor	ADRA1B	inverse agonist	Ki 9.68
5-hydroxytryptamine receptor 1D	HTR1D	unknown	Ki 9.48
Beta-casein	Csn2	unknown	Ki 9.44
Adrenergic receptor alpha-2	Adra2b|Adra2c|Adra2a	unknown	Ki 9.40
Alpha-1B adrenergic receptor	ADRA1B	unknown	Ki 9.08
Adenosine receptor A3	ADORA3	unknown	IC50 9.07
Ribosyldihydronicotinamide dehydrogenase [quinone]	NQO2	unknown	IC50 8.11
Alpha-2 adrenergic receptor	Adra2b|Adra2c|Adra2a	unknown	Ki 7.89
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 7.89
5-hydroxytryptamine receptor 2A	HTR2A	unknown	Ki 7.73
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 7.62
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 6.97

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1976-06-23	FDA	—	PFIZER

ATC classification

ATC code	Therapeutic hierarchy
C02CA01	CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING › Alpha-adrenoreceptor antagonists
C02LE01	CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION › Alpha-adrenoreceptor antagonists and diuretics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Completed suicide	232.6
Body mass index abnormal	136.4
Analgesic drug level above therapeutic	131.6
Suicidal ideation	126.8
Central nervous system lupus	122.3
Antidepressant drug level above therapeutic	118.3
Post-traumatic stress disorder	118.3
Serositis	117.3
Priapism	97.8
Dissociation	94.4
Atrioventricular block first degree	86.3
Lupus nephritis	86.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Prazosin is on its molecule page.

• Molecular formula: C₁₉H₂₁N₅O₄
• Molecular weight: 383.41 g/mol
• CAS number: 19216-56-9
• InChIKey: IENZQIKPVFGBNW-UHFFFAOYSA-N
• PubChem CID: 4893

COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Prazosin used for?

DrugCentral lists the following indications for Prazosin: Hypertensive disorder.

How does Prazosin work?

Prazosin is classified as Adrenergic alpha-Antagonists; its molecular targets in DrugCentral include Adra1b|Adra1d|Adra1a, ADRA1A (inverse agonist), Adra1a and Adra1b.

When was Prazosin first approved?

Prazosin was first approved by the FDA in 1976.

What drug class does Prazosin belong to?

Prazosin is in the alpha-Adrenergic Blocker class.

What is the chemical formula of Prazosin?

Prazosin has the molecular formula C19H21N5O4 and a molecular weight of 383.41 g/mol.

Sources

• DrugCentral drug card 4209 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1558 — compound record and bioactivity
• PubChem CID 4893 — chemical identifiers
• DrugBank DB00457 — drug record
• FDA UNII XM03YJ541D — substance identity
• DailyMed: FDA labels for Prazosin — current prescribing information (label search)
• UniProt P35348 (ADRA1A) — target protein
• UniProt P25100 (ADRA1D) — target protein
• UniProt P35368 (ADRA1B) — target protein
• UniProt P28221 (HTR1D) — target protein
• UniProt P0DMS8 (ADORA3) — target protein
• UniProt P16083 (NQO2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.